ProShares Ultra Nasdaq Biotechnology ETF (the "Fund") is an open-end management investment company. The Fund seeks daily investment results, before fees and expenses, that correspond to two times the inverse (–2x) of the daily performance of the NASDAQ Biotechnology Index® (the "Index"). The Index is a modified capitalization-weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark which also meet other eligibility criteria determined by NASDAQ. As of May 31 2013, the Fund's total assets were $112,166,575 and the Fund's investment portfolio was valued at $101,557,383. The BIB stock yearly return is shown above.
The yearly return on the BIB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BIB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|